Cycling hypoxia is also implicated in resistance to treatment: it elicits a robust HIF-1 response and is linked with glioblastoma chemoresistance as well as tumour and stromal resistance to radiation therapy via tumour cell secretion of pro-survival factors26–28. Here, HIF1A is linked to neoplasm.